ArticleScientific reports2025
Antibiotic therapy and clinical outcomes of penicillin-susceptible Staphylococcus aureus (PSSA) bloodstream infection (BSI): a ten-year retrospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the incidence of penicillin-susceptible S. aureus (PSSA) bloodstream infection (BSI) has increased worldwide. However, the preferred antibiotic remains uncertain due to concerns of inducible resistance to benzylpenicillin. We compared outcomes associated with benzylpenicillin versus other antibiotics and investigated risk factors influencing treatment failure. Patients were grouped into benzylpenicillin and non-benzylpenicillin beta-lactam treatment groups (including anti-staphylococcal penicillins and cephalosporins). The primary outcome was overall treatment failure (30-day all-cause mortality and/or 90-day relapse). Of 335 patients, 74 (22.09%) received benzylpenicillin and 261 (77.91%) received a non-benzylpenicillin beta-lactam. While rates of overall treatment failure (13.51% vs. 17.24%; P = 0.45) and occurrence of adverse drug events (6.76% vs. 7.66%; P = 0.79) were comparable to non-benzylpenicillin beta-lactams, benzylpenicillin showed faster microbiological clearance [3.00 days (IQR, 2.00-4.00 days) vs. 4.00 days (IQR, 3.00-5.00 days); P = 0.03] and fewer persistent infections (22.97% vs. 36.02%; P = 0.04), suggesting potential to improve patient outcomes. We also found that unknown source (aOR 4.63, 95% CI 1.47-14.64; P < 0.01) was associated with treatment failure, while review by Infectious Disease (ID) specialists (aOR 0.30, 95% CI 0.12-0.73; P = 0.01) was protective, stressing the importance of early ID referral and thorough source identification. This study highlights benzylpenicillin as an effective treatment for PSSA BSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.